查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1682229

显影剂与注射器系统市场：2025 年至 2035 年分析与预测

Global Contrast Media Agent and Injector Systems Market: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 120 Pages | 商品交期: 1-5个工作天内

价格
简介目录

全球显影剂和注射器系统市场对于现代诊断成像至关重要，它可以在电脑断层扫描、MRI、X 光和超音波检查等过程中更清晰地显示内部身体结构。

显影剂是注射到体内的特殊物质，可以提高影像的清晰度，使医疗专业人员能够更有效地检测异常情况。显影剂的使用对于各种诊断影像技术至关重要，可确保详细且准确的诊断。随着全球医疗保健需求的不断增长，加上影像技术的进步，对显影剂及其输送系统的需求也不断增长，巩固了显影剂在临床实践中的重要性。

有几个因素推动了全球显影剂和注射器系统市场的发展。首先，癌症、心血管和神经系统疾病等慢性疾病的发生率不断上升，推动了对先进成像技术的需求，而这些技术需要显影剂才能获得最佳效果。根据世界卫生组织 (WHO) 统计，仅癌症每年就会导致数亿人死亡，这凸显了早期发现的必要性，而这在很大程度上依赖于显影剂的使用。其次，3T MRI 和 4D 电脑断层扫描等影像技术的不断进步，需要使用更复杂、更高品质的显影剂来提供更清晰、更详细的影像。第三，世界人口老化将导致诊断影像的频率增加，进一步增加对有效显影剂的需求。最后，对提高诊断准确性和早期发现疾病的需求不断增长，显影剂对于医疗保健系统至关重要。

儘管存在显着的成长动力，显影剂和注射器系统市场仍面临许多挑战。主要担心的是显影剂的潜在副作用，包括过敏反应和肾毒性。这种安全性问题可能会限制某些显影剂的使用，尤其是对于已有疾病的患者，从而限制其市场应用。此外，显影剂和相关影像程序的高成本也构成了障碍，特别是在医疗预算有限的中低收入国家。此外，监管挑战可能会减缓市场引入速度，因为获得新显影剂和注射系统的核准既费时又昂贵。

显影剂和注射器系统市场存在着许多机会。随着亚太地区和非洲部分地区等新兴市场获得诊断影像的机会不断增加，预计医疗保健基础设施的扩大将推动对显影剂的需求。此外，精准医疗的兴起，专注于为个别患者制定个人化治疗，推动了对能够提供准确诊断结果的更专业的显影剂的需求。奈米技术在分子层面设计显影剂以提供更高的精度，而人工智慧（AI）领域的创新正在改变成像系统，为市场带来令人兴奋的机会。奈米粒子显影剂有望透过实现更高的灵敏度和更高解析度的扫描彻底改变成像技术，为医疗保健专业人员开闢新的途径。

本报告研究了全球显影剂和注射器系统市场，并概述了市场状况以及按产品、应用、最终用户和地区分類的趋势，以及参与市场的公司概况。

目录

执行摘要

研究范围

第 1 章 全球显影剂与注射器系统市场概述

  • 市场展望
  • 产业展望
  • 市场动态

2. 2024 年至 2035 年全球显影剂和注射器系统市场规模分析（美元）

  • 市场概况
  • 成长型股市
  • 显影剂
  • 喷射系统

3. 2024 年至 2035 年全球显影剂和注射器系统市场规模分析（美元）

  • 市场概况
  • 成长型股市
  • 放射科
  • 心臟病学
  • 肿瘤学
  • 神经科
  • 其他（泌尿系统、胃肠科等）

4. 2024 年至 2035 年全球显影剂和注射器系统市场规模分析（美元），按最终用户划分

  • 市场概况
  • 成长型股市
  • 医院
  • 诊断影像中心
  • 其他（ASC、研究机构等）

5. 2024 年至 2035 年全球显影剂和注射器系统市场规模分析（美元），按地区划分

  • 市场概况

6. 全球显影剂和注射器系统市场竞争基准化分析和公司概况

  • 竞争性基准化分析
  • 竞争格局
    • 各公司的主要策略和发展
    • 关键进展
    • 2024 年市场占有率分析
  • 公司简介
    • Bayer AG
    • Beijing Beilu Pharmaceutical Co. Ltd.
    • Bracco Group
    • Fresenius SE & Co. KGaA
    • FUJIFILM Holdings Corporation
    • General Electric Company
    • Guerbet
    • Jiangsu Hengrui Pharmaceutical Co., Ltd
    • Jodas Expoim Pvt. Ltd
    • Lantheus Holdings, Inc.
    • Shenzen Seacrown Electromechanical Co., Ltd
    • Sino Medical-Device Technology Co., Ltd
    • ulrich GmbH & Co. KG
    • Unijules Life Sciences Ltd
    • 其他主要企业
简介目录
Product Code: BHR1401SB

Global Contrast Media Agent and Injector System Market Industry Overview

The global contrast media agent and injector system market is integral to modern diagnostic imaging, providing enhanced visualization of internal body structures during procedures like CT scans, MRIs, X-rays, and ultrasounds. Contrast media agents are specialized substances injected into the body to improve the clarity of images, allowing healthcare professionals to detect abnormalities more effectively. The use of contrast media agents is crucial for a variety of imaging techniques, ensuring detailed and accurate diagnostics. As healthcare needs increase globally, coupled with advancements in imaging technology, the demand for contrast media agents and their delivery systems is rising, solidifying their importance in clinical practice.

Several factors are driving the global contrast media agent and injector system market. First, the growing prevalence of chronic diseases, such as cancer, cardiovascular disease, and neurological disorders, has elevated the demand for advanced imaging technologies that require contrast media agents for optimal results. According to the World Health Organization (WHO), cancer alone accounts for millions of deaths each year, emphasizing the need for early detection, which heavily relies on the use of contrast media agents. Second, continuous advancements in imaging technologies, such as 3T MRIs and 4D CT scans, necessitate the use of more sophisticated and higher-quality contrast media agents to deliver clearer, more detailed images. Third, the aging global population is leading to an increased frequency of diagnostic imaging procedures, further boosting the need for effective contrast media agents. Lastly, the rising demand for greater diagnostic accuracy and early disease detection is making contrast media agents indispensable in the healthcare system.

Despite the substantial growth drivers, the contrast media agent and injector system market for contrast media agents faces several challenges. A major concern is the potential for adverse reactions to contrast media agents, including allergic reactions or nephrotoxicity. These safety concerns can restrict the use of certain contrast media agents, particularly in patients with pre-existing conditions, which in turn limits their market adoption. Furthermore, the high cost of contrast media agents and the associated imaging procedures can act as a barrier, especially in low- and middle-income countries where healthcare budgets are more constrained. Regulatory hurdles also pose challenges, as obtaining approval for new contrast media agents and injector systems can be a lengthy and costly process, delaying their introduction to the market.

The contrast media agent and injector system market presents numerous opportunities. The growing healthcare infrastructure in emerging markets, such as Asia-Pacific and parts of Africa, is expected to boost demand for contrast media agents as these regions expand access to diagnostic imaging. Additionally, the rise of precision medicine, which focuses on tailoring treatments to individual patients, is driving the demand for more specialized contrast media agents that can provide precise diagnostic results. Innovations in nanotechnology, where contrast media agents are designed at the molecular level to offer higher precision, and artificial intelligence (AI), which is transforming imaging systems, present exciting opportunities for the market. Nanoparticle-based contrast media agents are expected to revolutionize imaging techniques by enabling higher sensitivity and resolution in scans, opening new avenues for healthcare professionals.

Global Contrast Media Agent and Injector System Market Lifecycle Stage

The global contrast media agent and injector system market is experiencing significant growth, with multiple collaborations between key market players aimed at combining resources, expanding customer bases, and enhancing marketing efforts. This growth is further supported by continuous research and development focused on creating innovative products. Additionally, many pharmaceutical companies are broadening their operations and becoming more outsourcing-oriented, which is helping to drive the expansion of the contrast media agent and injector system market.

Industry and Technology Overview

Market Segmentation:

Segmentation 1: by Product

  • Contrast Media Agents
  • Injector Systems

The global contrast media agent and injector system market (by product) is expected to be dominated by the contrast media agents segment.

  • Contrast Media Agents (by Modality)
    • X-Ray/CT Scan
    • MRI
    • Ultrasound

The global contrast media agent market (by modality) is expected to be dominated by the X-Ray/CT scan.

  • Contrast Media Agents (by Type of Media Agent)
    • Iodine-Based Contrast Media Agent
    • Gadolinium-Based Contrast Media Agent
    • Barium-Based Contrast Media Agent
    • Microbubble Contrast Media Agent
    • Others

The global contrast media agent market (by type of media agent) is expected to be dominated by iodine-based contrast media agent.

  • Injector Systems (by Modality)
    • CT Injector Systems
    • MRI Injector Systems
    • Cardiovascular/Angiography Injector Systems

The global contrast media injector system market (by modality) is expected to be dominated by CT injector systems.

  • Injector Systems (by Product)
    • Injector
    • Consumables and Accessories

The global contrast media injector system market (by product) is expected to be dominated by consumables and accessories.

  • Injector Systems (by Injector Type)
    • Single-Head Injectors
    • Dual-Head Injectors
    • Syringeless Injectors

The global contrast media injector system market (by injector type) is expected to be dominated by single-head injectors.

Segmentation 2: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The global contrast media agent and injector system market (by region) is dominated by the North America region.

Recent Developments in Global Contrast Media Agent and Injector System Market

  • In January 2023, Bayer AG received European approval for its iodine-based contrast agents, Ultravist-300 and Ultravist-370, for use in contrast-enhanced mammography (CEM).
  • In December 2022, Beijing Beilu Pharmaceutical Co. Ltd. expanded its operations by establishing a wholly-owned subsidiary in Hong Kong.
  • In April 2022, Beijing Beilu Pharmaceutical Co., Ltd. received the ""Drug Registration Certificate"" from the National Medical Products Administration (NMPA) for its gadobutrol injection.
  • In February 2023, Bracco Group formed a partnership with Wellstar Health System to conduct trials for its FDA-approved VUEWAY (gadopiclenol) injection, a contrast agent designed for MRI applications.
  • In February 2023, Bracco Group acquired all shares of Bracco-Eisai from Eisai and subsequently rebranded the company as Bracco Japan, Ltd.
  • In July 2022, Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA, launched its line of generic contrast media agents in the U.S.
  • In December 2022, General Electric Company partnered with ulrich GmbH & Co. KG to introduce a branded multi-dose contrast media injector in the U.S. market.

Demand - Drivers and Limitations

The following are the drivers for the global contrast media agent and injector system market:

  • Increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector system
  • Upsurge in demand for image-guided diagnostics
  • Growing number of regulatory approvals

The global contrast media agent and injector system market is expected to face some limitations as well due to the following challenges:

  • Rising health concerns post usage of contrast media agents in the body

How can this report add value to an organization?

Growth/Marketing Strategy: The global contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The global contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies have the opportunity to expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals.

Competitive Landscape

The contrast media agent and injector system market is highly competitive, with major players focusing on product innovation and strategic expansion.

Contrast Media Agent And Injector System Key Market Players and Competition Synopsis:

  • Bayer AG
  • Fresenius SE & Co. KGaA
  • FUJIFILM Visualsonics, Inc (Fujifilm Holdings Corporation)
  • General Electric Company
  • Lantheus Medical Imaging
  • Guerbet
  • Bracco Group
  • J.B. Chemicals and Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • ulrich GmbH & Co. KG
  • ShenzenSeacrown Electromechanical Co Ltd
  • Jodas Expoim Pvt. Ltd.
  • Beijing Beilu Pharmaceutical Co. Ltd
  • MEDTRON AG
  • SINO MDT
  • Stanex Drugs & Chemical Pvt. Ltd.
  • Taejoon Pharm
  • Nano Therapeutics Pvt. Ltd.
  • Nemoto Kyorindo Co., Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Contrast Media Agent and Injector Systems Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Definitions
    • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.3 Market Size, 2024 - 2035 (US$)
    • 1.1.4 Market Growth Scenario
      • 1.1.4.1 Realistic Scenario
      • 1.1.4.2 Optimistic Scenario
      • 1.1.4.3 Pessimistic Scenario
  • 1.2 Industry Outlook
    • 1.2.1 Market Overview
    • 1.2.2 Market Ecosystem
    • 1.2.3 Regulatory Landscape
      • 1.2.3.1 Regulatory and Legal Requirements and Framework in the U.S.
      • 1.2.3.2 Regulatory and Legal Requirements and Framework in Europe
      • 1.2.3.3 Regulatory and Legal Requirements and Framework in Asia-Pacific
      • 1.2.3.4 Regulatory and Legal Requirements and Framework in Other Key Countries
    • 1.2.4 Patent Analysis
      • 1.2.4.1 Patent Filing Trend (by Year)
      • 1.2.4.2 Patent Filing Trend (by Country)
  • 1.3 Market Dynamics
    • 1.3.1 Market Key Trends
    • 1.3.2 Market Drivers
      • 1.3.2.1 Impact Analysis
    • 1.3.3 Market Restraints
      • 1.3.3.1 Impact Analysis
    • 1.3.4 Market Opportunities
      • 1.3.4.1 Impact Analysis

2. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Product Type

  • 2.1 Market Overview
  • 2.2 Growth Share Market
  • 2.3 Contrast Media Agent
    • 2.3.1 By Modality
      • 2.3.1.1 X-Ray/CT scan
      • 2.3.1.2 MRI
      • 2.3.1.3 Ultrasound
    • 2.3.2 By Type of Media Agent
      • 2.3.2.1 Iodine-Based Contrast Media Agent
      • 2.3.2.2 Gadolinium-Based Contrast Media Agent
      • 2.3.2.3 Barium-Based Contrast Media Agent
      • 2.3.2.4 Microbubble Contrast Media Agent
      • 2.3.2.5 Others
  • 2.4 Injector System
    • 2.4.1 By Product
      • 2.4.1.1 Injector
      • 2.4.1.2 Consumable and Accessories
    • 2.4.2 By Modality
      • 2.4.2.1 CT Injector Systems
      • 2.4.2.2 MRI Injector Systems
      • 2.4.2.3 Cardiovascular/Angiography Injector Systems
    • 2.4.3 By Injector Type
      • 2.4.3.1 Single Head Injectors
      • 2.4.3.2 Dual Head Injectors
      • 2.4.3.3 Syringeless Injectors

3. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Application

  • 3.1 Market Overview
  • 3.2 Growth Share Market
  • 3.3 Radiology
  • 3.4 Cardiology
  • 3.5 Oncology
  • 3.6 Neurology
  • 3.7 Others (Urology, Gastroenterology, etc.)

4. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by End User

  • 4.1 Market Overview
  • 4.2 Growth Share Market
  • 4.3 Hospitals
  • 4.4 Diagnostic Imaging Centers
  • 4.5 Others (ASCs, Research Institutes, etc.)

5. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Region

  • 5.1 Market Overview
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Size and Forecast
      • 5.1.2.1 North America Contrast Media Agent and Injector Systems Market
        • 5.1.2.1.1 Key Findings
        • 5.1.2.1.2 Market Dynamics
        • 5.1.2.1.3 Impact Analysis
        • 5.1.2.1.4 Market Sizing and Forecast
          • 5.1.2.1.4.1 North America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.2 North America Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3 North America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.1.4.3.1 U.S.
          • 5.1.2.1.4.3.1.1 U.S. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.1.2 U.S. Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3.2 Canada.
          • 5.1.2.1.4.3.2.1 Canada Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.2.2 Canada Contrast Media Injector System Market (by Product)
      • 5.1.2.2 Europe Contrast Media Agent and Injector Systems Market
        • 5.1.2.2.1 Key Findings
        • 5.1.2.2.2 Market Dynamics
        • 5.1.2.2.3 Impact Analysis
        • 5.1.2.2.4 Market Sizing and Forecast
          • 5.1.2.2.4.1 Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.2 Europe Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3 Europe Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.2.4.3.1 U.K.
          • 5.1.2.2.4.3.1.1 U.K. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.1.2 U.K. Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.2 Germany.
          • 5.1.2.2.4.3.2.1 Germany Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.2.2 Germany Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.3 France
          • 5.1.2.2.4.3.3.1 France Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.3.2 France Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.4 Italy
          • 5.1.2.2.4.3.4.1 Italy Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.4.2 Italy Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.5 Spain
          • 5.1.2.2.4.3.5.1 Spain. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.5.2 Spain Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.6 Rest of Europe.
          • 5.1.2.2.4.3.6.1 Rest of Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.6.2 Rest of Europe Contrast Media Injector System Market (by Product)
      • 5.1.2.3 Asia-Pacific Contrast Media Agent and Injector Systems Market
        • 5.1.2.3.1 Key Findings
        • 5.1.2.3.2 Market Dynamics
        • 5.1.2.3.3 Impact Analysis
        • 5.1.2.3.4 Market Sizing and Forecast
          • 5.1.2.3.4.1 Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.2 Asia-Pacific Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3 Asia-Pacific Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.3.4.3.1 China
          • 5.1.2.3.4.3.1.1 China Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.1.2 China Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.2 Japan
          • 5.1.2.3.4.3.2.1 Japan Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.2.2 Japan Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.3 India
          • 5.1.2.3.4.3.3.1 India Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.3.2 India Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.4 Australia
          • 5.1.2.3.4.3.4.1 Australia Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.4.2 Australia Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.5 South Korea
          • 5.1.2.3.4.3.5.1 South Korea Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.5.2 South Korea Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.6 Rest-of- Asia-Pacific
          • 5.1.2.3.4.3.6.1 Rest-of-Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.6.2 Rest-of-Asia-Pacific Contrast Media Injector System Market (by Product)
      • 5.1.2.4 Latin America Contrast Media Agent and Injector Systems Market
        • 5.1.2.4.1 Key Findings
        • 5.1.2.4.2 Market Dynamics
        • 5.1.2.4.3 Impact Analysis
        • 5.1.2.4.4 Market Sizing and Forecast
          • 5.1.2.4.4.1 Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.2 Latin America Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3 Latin America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.4.4.3.1 Brazil
          • 5.1.2.4.4.3.1.1 Brazil Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.1.2 Brazil Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.2 Mexico
          • 5.1.2.4.4.3.2.1 Mexico Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.2.2 Mexico Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.3 Rest-of-Latin America
          • 5.1.2.4.4.3.3.1 Rest-of-Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.3.2 Rest-of-Latin America Contrast Media Injector System Market (by Product)
      • 5.1.2.5 Middle East and Africa Contrast Media Agent and Injector Systems Market
        • 5.1.2.5.1 Key Findings
        • 5.1.2.5.2 Market Dynamics
        • 5.1.2.5.3 Impact Analysis
        • 5.1.2.5.4 Market Sizing and Forecast
          • 5.1.2.5.4.1 Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.2 Middle East and Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3 Middle East and Africa Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.5.4.3.1 UAE
          • 5.1.2.5.4.3.1.1 UAE Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.1.2 UAE Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.2 South Africa
          • 5.1.2.5.4.3.2.1 South Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.2.2 South Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.3 Rest-of-MEA
          • 5.1.2.5.4.3.3.1 Rest-of-Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.3.2 Rest-of-Middle East and Africa Contrast Media Injector System Market (by Product)

6. Global Contrast Media Agent and Injector Systems Market- Competitive Benchmarking and Company Profiles

  • 6.1 Competitive Benchmarking
  • 6.2 Competitive Landscape
    • 6.2.1 Key Strategies and Developments by Company
      • 6.2.1.1 Funding Activities
      • 6.2.1.2 Mergers and Acquisitions
      • 6.2.1.3 Regulatory Approvals
      • 6.2.1.4 Partnerships, Collaborations, and Business Expansions
    • 6.2.2 Key Developments Analysis
    • 6.2.3 Market Share Analysis, 2024
  • 6.3 Company Profiles
    • 6.3.1 Bayer AG
      • 6.3.1.1 Company Overview
      • 6.3.1.2 Product Portfolio/Offering
      • 6.3.1.3 Key Competitors
      • 6.3.1.4 Analyst View
    • 6.3.2 Beijing Beilu Pharmaceutical Co. Ltd.
      • 6.3.2.1 Company Overview
      • 6.3.2.2 Product Portfolio/Offering
      • 6.3.2.3 Key Competitors
      • 6.3.2.4 Analyst View
    • 6.3.3 Bracco Group
      • 6.3.3.1 Company Overview
      • 6.3.3.2 Product Portfolio/Offering
      • 6.3.3.3 Key Competitors
      • 6.3.3.4 Analyst View
    • 6.3.4 Fresenius SE & Co. KGaA
      • 6.3.4.1 Company Overview
      • 6.3.4.2 Product Portfolio/Offering
      • 6.3.4.3 Key Competitors
      • 6.3.4.4 Analyst View
    • 6.3.5 FUJIFILM Holdings Corporation
      • 6.3.5.1 Company Overview
      • 6.3.5.2 Product Portfolio/Offering
      • 6.3.5.3 Key Competitors
      • 6.3.5.4 Analyst View
    • 6.3.6 General Electric Company
      • 6.3.6.1 Company Overview
      • 6.3.6.2 Product Portfolio/Offering
      • 6.3.6.3 Key Competitors
      • 6.3.6.4 Analyst View
    • 6.3.7 Guerbet
      • 6.3.7.1 Company Overview
      • 6.3.7.2 Product Portfolio/Offering
      • 6.3.7.3 Key Competitors
      • 6.3.7.4 Analyst View
    • 6.3.8 Jiangsu Hengrui Pharmaceutical Co., Ltd
      • 6.3.8.1 Company Overview
      • 6.3.8.2 Product Portfolio/Offering
      • 6.3.8.3 Key Competitors
      • 6.3.8.4 Analyst View
    • 6.3.9 Jodas Expoim Pvt. Ltd
      • 6.3.9.1 Company Overview
      • 6.3.9.2 Product Portfolio/Offering
      • 6.3.9.3 Key Competitors
      • 6.3.9.4 Analyst View
    • 6.3.10 Lantheus Holdings, Inc.
      • 6.3.10.1 Company Overview
      • 6.3.10.2 Product Portfolio/Offering
      • 6.3.10.3 Key Competitors
      • 6.3.10.4 Analyst View
    • 6.3.11 Shenzen Seacrown Electromechanical Co., Ltd
      • 6.3.11.1 Company Overview
      • 6.3.11.2 Product Portfolio/Offering
      • 6.3.11.3 Key Competitors
      • 6.3.11.4 Analyst View
    • 6.3.12 Sino Medical-Device Technology Co., Ltd
      • 6.3.12.1 Company Overview
      • 6.3.12.2 Product Portfolio/Offering
      • 6.3.12.3 Key Competitors
      • 6.3.12.4 Analyst View
    • 6.3.13 ulrich GmbH & Co. KG
      • 6.3.13.1 Company Overview
      • 6.3.13.2 Product Portfolio/Offering
      • 6.3.13.3 Key Competitors
      • 6.3.13.4 Analyst View
    • 6.3.14 Unijules Life Sciences Ltd
      • 6.3.14.1 Company Overview
      • 6.3.14.2 Product Portfolio/Offering
      • 6.3.14.3 Key Competitors
      • 6.3.14.4 Analyst View
    • 6.3.15 Other Key Companies